TYNA-1 is being developed as a first-line prescription therapy to treat the two leading causes of preventable deaths worldwide – tobacco addiction and obesity. We believe this proprietary, non-addictive, novel cannabinoid analog will be the first successful treatment to control these diseases. Treatment of the initial indication, smoking cessation, including smokeless tobacco and nicotine addiction, will be available in oral pill form.
Company Details
- Founded
- -
- Address
- 855 N Wolfe St,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://tynapharma.com/
- HQ
- Baltimore, Maryland
Tyna Pharmaceuticals Inc. Questions
Tyna Pharmaceuticals Inc.'s website is https://tynapharma.com/
Tyna Pharmaceuticals Inc.'s LinkedIn profile is https://www.linkedin.com/company/tyna-pharmaceuticals-inc
Tyna Pharmaceuticals Inc.'s industry is
Biotechnology Research
Tyna Pharmaceuticals Inc.'s top competitors are
Ernest Pharmaceuticals,
Inflexion Pharmaceuticals Llc,
Millenium Pharmaceuticals,
Arya Pharmaceuticals,
Raft Pharmaceuticals,
Sacyl Pharmaceuticals, Inc.,
Nelson Pharmaceuticals, Llc,
Inspira Pharmaceuticals Limited,
Mountain View Pharmaceuticals, Inc.,
Rich Pharmaceuticals, Inc..
Tyna Pharmaceuticals Inc.'s categories are Biotechnology Research
Tyna Pharmaceuticals Inc.'s founding year is 2022
